mfn-cus-kl1333 – Page 2

1 June, 2020

Abliva arranges virtual Capital Markets Day on 23 June

Abliva AB (Nasdaq Stockholm: ABLI), invites to a virtual capital markets day on 23 June at 3.00 - 4.30 p.m. CEST. The theme of the day will be the company's new strategic focus on primary mitochondria ...

28 May, 2020

NeuroVive Pharmaceutical changes its name to Abliva

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) announced today that the company’s application for a change of name to Abliva AB (publ) has been approved by the Swedish Companies Registration Offi ...

20 May, 2020

Regulatory

Interim Report January-March 2020

Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for […]

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...